Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686089 | 0.80 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL3685263 | 0.75 | MEN1 (0.41) | MMP8MGAMGAASIMGAM2 | |
| SCHEMBL234361 | 0.73 | MMP8 (0.41) | MMP8DGAT1GAA | |
| SCHEMBL10054497 | 0.72 | — | — | |
| SCHEMBL809243 | 0.71 | DGAT1 (0.40) | DGAT1MGAMGAASIMGAM2 | |
| SCHEMBL30992192 | 0.71 | KCNN4 (0.49) | — | |
| SCHEMBL2650988 | 0.71 | DGAT1 (0.39) | MMP8DGAT1PKM | |
| SCHEMBL30992195 | 0.70 | MEN1 (0.37) | EPHX1GAA | |
| SCHEMBL30992207 | 0.70 | KCNN4 (0.47) | MMP8 | |
| SCHEMBL29674742 | 0.69 | DGAT1 (0.39) | DGAT1MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | DHPS, ALG8, DDOST | MMP8 3418/4885EPHX1 1039/4885DGAT1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.